Head to Head Contrast: Artelo Biosciences (NASDAQ:ARTL) versus CSL (OTCMKTS:CSLLY)

Artelo Biosciences (NASDAQ:ARTLGet Free Report) and CSL (OTCMKTS:CSLLYGet Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Artelo Biosciences and CSL, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Artelo Biosciences 0 0 1 0 3.00
CSL 0 0 0 0 N/A

Artelo Biosciences currently has a consensus target price of $5.00, indicating a potential upside of 290.63%. Given Artelo Biosciences’ higher probable upside, equities research analysts plainly believe Artelo Biosciences is more favorable than CSL.

Insider and Institutional Ownership

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 0.0% of CSL shares are held by institutional investors. 6.9% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Artelo Biosciences has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, CSL has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500.


This table compares Artelo Biosciences and CSL’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Artelo Biosciences N/A -61.68% -58.15%

Valuation & Earnings

This table compares Artelo Biosciences and CSL’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Artelo Biosciences N/A N/A -$9.29 million ($3.14) -0.41
CSL $13.31 billion 6.31 $2.19 billion N/A N/A

CSL has higher revenue and earnings than Artelo Biosciences.


Artelo Biosciences beats CSL on 5 of the 9 factors compared between the two stocks.

About Artelo Biosciences

(Get Free Report)

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

About CSL

(Get Free Report)

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.